Research programme: antisense therapies - AstraZeneca/Ionis Pharmaceuticals

Drug Profile

Research programme: antisense therapies - AstraZeneca/Ionis Pharmaceuticals

Alternative Names: AZD 2693; AZD-2373; AZD-8233; IONIS-AZ4-2.5-LRx; IONIS-AZ5-2.5Rx; IONIS-AZ6-2.5-LRx; ISIS 581088

Latest Information Update: 12 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer AstraZeneca; Ionis Pharmaceuticals
  • Class Antineoplastics; Antisense oligonucleotides; Cardiovascular therapies; Hepatoprotectants
  • Mechanism of Action Androgen receptor antagonists; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Cardiovascular disorders; Non-alcoholic steatohepatitis
  • Research Kidney disorders; Metabolic disorders

Most Recent Events

  • 20 Jul 2018 AstraZeneca and Parexel plan a phase I trial of AZD 8233 for Hypercholesterolaemia (In volunteers) in USA (SC), in July 2018 (NCT03593785),
  • 10 Apr 2018 Ionis Pharmaceuticals licenses IONIS-AZ6-2.5-LRx (AZD 2693) to AstraZeneca for development and commercialisation
  • 10 Apr 2018 Preclinical trials in Non-alcoholic steatohepatitis in USA (unspecified route) before April 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top